If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> European Edition<br /> HEMATOLOGY<br /> Suppl. 2 May 2020 emjreviews.com<br /> + ICML 2019<br /> Antibody Therapies for<br /> Patients With Diffuse Large<br /> B-cell Lymphoma: What Does<br /> the Future Hold?<br /> Antibody Therapies for Patients With Diffuse Large<br /> B-cell Lymphoma: What Does the Future Hold?<br /> This symposium took place on 18th June 2019, as part of the 15th<br /> International Congress on Malignant Lymphoma (ICML)<br /> in Lugano, Switzerland<br /> Chairpeople: Laurie H. Sehn1<br /> Speakers: Armando López-Guillermo,2 Matthew Matasar,3 Franck Morschhauser,4<br /> Laurie H. Sehn,1 Andrew McMillan5<br /> 1. British Columbia Cancer Centre for Lymphoid Cancer and University of British<br /> Columbia, Vancouver, Canada<br /> 2. Department of Hematology, Hospital Clínic of Barcelona, Barcelona, Spain<br /> 3. Memoria<a title="EMJ Hematology. 2020 Suppl 2 page 1" href="http://viewer.zmags.com/publication/111120a2?page=1"> European Edition HEMATOLOGY Suppl. 2 May 202</a> <a title="EMJ Hematology. 2020 Suppl 2 page 2" href="http://viewer.zmags.com/publication/111120a2?page=2"> Antibody Therapies for Patients With Diffuse Larg</a> <a title="EMJ Hematology. 2020 Suppl 2 page 3" href="http://viewer.zmags.com/publication/111120a2?page=3"> chemotherapy. R-CHOP was later approved as first-l</a> <a title="EMJ Hematology. 2020 Suppl 2 page 4" href="http://viewer.zmags.com/publication/111120a2?page=4"> The only positive trial published comparing </a> <a title="EMJ Hematology. 2020 Suppl 2 page 5" href="http://viewer.zmags.com/publication/111120a2?page=5"> R-DHAP (dexamethasone, cytarabine, cisplatin) ver</a> <a title="EMJ Hematology. 2020 Suppl 2 page 6" href="http://viewer.zmags.com/publication/111120a2?page=6"> antibody field; potential B-cell targets include a</a> <a title="EMJ Hematology. 2020 Suppl 2 page 7" href="http://viewer.zmags.com/publication/111120a2?page=7"> There are many different BsAb constructs with dif</a> <a title="EMJ Hematology. 2020 Suppl 2 page 8" href="http://viewer.zmags.com/publication/111120a2?page=8"> and degradation by lysosomes. The release of the </a> <a title="EMJ Hematology. 2020 Suppl 2 page 9" href="http://viewer.zmags.com/publication/111120a2?page=9"> Proportion of event-free patients N=46; long-ter</a> <a title="EMJ Hematology. 2020 Suppl 2 page 10" href="http://viewer.zmags.com/publication/111120a2?page=10"> Secondary outcome measures include event-free sur</a> <a title="EMJ Hematology. 2020 Suppl 2 page 11" href="http://viewer.zmags.com/publication/111120a2?page=11"> 2005;23(18):4117-26. 13. Thieblemont C et al. N</a> <a title="EMJ Hematology. 2020 Suppl 2 page 12" href="http://viewer.zmags.com/publication/111120a2?page=12"> 2019;20(1):31-42. 48. Schuster SJ. Tisagenlecleu</a> <a title="EMJ Hematology. 2020 Suppl 2 page 13" href="http://viewer.zmags.com/publication/111120a2?page=13"> Oncology (ASCO) 2018, 1-5 June, 2018. 87. Sehn L</a>